The CHMP recommends conditional marketing authorization of REGN's linvoseltamab to treat adults with relapsed and refractory multiple myeloma.

At the heart of the controversy is Regeneron's alleged practice of paying credit card fees to distributors, on the condition that these fees were not passed on to Eylea customers. This arrangement, ...

Shares of Regeneron Pharmaceuticals Inc. REGN shed 1.99% to $684.87 Monday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index SPX falling 1.76% to ...

The Mineola Board of Education recognized Fatimah Badoolah, a senior at Mineola High School, who is a 2025 Regeneron Science ...

A lawsuit was filed for certain investors in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) shares. Investors who purchased shares of Regeneron ...

Regeneron Pharmaceuticals said on Monday its experimental gene therapy showed improved hearing in 10 of 11 children between ...

Ten of 11 children born with a rare form of congenital hearing loss experienced improvements after receiving the company’s ...

A gene therapy from Regeneron Pharmaceuticals Inc. improved hearing in nearly all deaf children in a clinical trial, results ...

The general mood among these heavyweight investors is divided, with 62% leaning bullish and 18% bearish. Among these notable ...

Regeneron's DB-OTO gene therapy shows improved hearing in 10 of 11 children in the CHORD trial, with three reaching ...

Regeneron has won a court ruling that will make it harder for U.S. authorities to win a lawsuit accusing it of paying illegal ...